Gilead Sciences has announced that the FDA has approved Zydelig (idelalisib) in combination with rituximab for patients with relapsed chronic lymphocytic leukemia for whom rituximab alone would be considered appropriate therapy, as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma, and for small lymphocytic lymphoma who have received at least two prior systemic therapies.

Zydelig is a first-in-class oral inhibitor of PI3K delta, a protein which plays a role in the activation, proliferation, and viability of B cells.

RELATED: Hematologic Cancers Resource Center


Continue Reading

Zydelig will be available in 100mg and 150mg strength tablets.

For more information call (800) 445-3235 or visit Gilead.com.

This article originally appeared on MPR